NEW YORK and MELBOURNE, Australia, Oct. 27, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the United States Patent and Trademark Office (USPTO) has granted a key patent covering the use of the Company's proprietary adult Mesenchymal Precursor Cells (MPCs) for the formation and repair of blood vessels in ischemic tissues.
US Patent No. 9,169,466 entitled 'Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation' provides commercial rights in the United States through to 8 January 2025 in line with adjustments. Further patent term extension may occur along with regulatory exclusivity extensions.
The granted claims cover the use of the Company's allogeneic or off-the-shelf MPCs obtained from any source, for use in conditions including ischemic heart disease, stroke and peripheral arterial disease.
Mesoblast has also been previously granted patents in Europe (EP1613335) and Japan (2006-503990), derived from the same patent family, which provides the Company with exclusive commercial rights in these two other major healthcare markets to at least 29 March 2024.
This newly granted patent extends and broadens Mesoblast's intellectual property position in the United States with respect to the treatment of cardiac and vascular diseases beyond the previously granted patents US7514074, US7892829, US8158120, US8158121, US8852570, US8852571, US8852572, US8852573, US8852574 and US8852575 which cover allogeneic culture-expanded Mesenchymal Stem Cell product candidates for cardiovascular diseases.
Mesoblast has more than 661 patents or patent applications across at least 72 patent families which provide substantial competitive advantages for the commercial development of cellular therapy products based on mesenchymal lineage cells.
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) is a global leader in innovative cellular medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target significantly advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic/inflammatory disorders and oncology/hematology conditions.
CONTACT: Julie Meldrum Global Head of Corporate Communications Mesoblast Limited T: +61 3 9639 6036 E: email@example.comSource: Mesoblast